A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Legend Biotech Corp
LEGN
$8.2B
Mkt Cap
$22.22
-5.57%
Legend Biotech Corp (LEGN) has a 5-year average return on invested capital (ROIC) of -29.2%. This is below average and may indicate limited pricing power.
Legend Biotech Corp (LEGN) has a market capitalization of $8.2B. It is classified as a mid-cap stock.
Legend Biotech Corp (LEGN) does not currently pay a regular dividend.
Legend Biotech Corp (LEGN) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Legend Biotech Corp (LEGN) reported annual revenue of $627 million in its most recent fiscal year, based on SEC EDGAR filings.
Legend Biotech Corp (LEGN) has a net profit margin of -28.2%. The company is currently unprofitable.
Legend Biotech Corp (LEGN) generated $-158 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Not Applicable.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 627M | 627M | 285M | - | - | 0 |
| Net Income | -177M | -177M | -518M | -446M | -404M | -266M |
| EPS | $-0.48 | $-0.48 | $-1.47 | $-1.40 | $-1.43 | $-1.13 |
| Free Cash Flow | -158M | -158M | -413M | -222M | -241M | -249M |
| ROIC | -16.6% | -17.0% | -41.4% | - | - | - |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.61 | 0.48 | - | - | - |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -158M | -158M | -520M | -446M | -407M | -308M |
| Operating Margin | -25.2% | -25.2% | -182.4% | - | - | - |
| ROE | -17.0% | -15.4% | -51.9% | - | - | - |
| Shares Outstanding | 369M | 369M | 353M | 319M | 282M | 236M |
| Metric | 2018 | 2019 | TTM | |||||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 49M | 60M | 0 | N/A | N/A | 285M | 627M | 627M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 61M | 162M | 232M | 313M | 336M | 382M | 414M | 414M |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -1.6M | -127M | -308M | -407M | -446M | -520M | -158M | -158M |
| Op. Margin | -3.3% | -212.3% | N/A | N/A | N/A | -182.4% | -25.2% | -25.2% |
| Net Income | -2.8M | -102M | -266M | -404M | -446M | -518M | -177M | -177M |
| Net Margin | -5.7% | -169.4% | N/A | N/A | N/A | -181.8% | -28.2% | -28.2% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | -43.3% | N/A | N/A | N/A | N/A | -41.4% | -17.0% | -16.6% |
| ROE | N/A | N/A | N/A | N/A | N/A | -51.9% | -15.4% | -17.0% |
| ROA | -74.6% | -365.6% | -673.6% | -1054.2% | -802.9% | -54.4% | -10.1% | -10.6% |
| Cash Flow | ||||||||
| Op. Cash Flow | 308M | -83M | -223M | -198M | -201M | -393M | -144M | -144M |
| Free Cash Flow | 287M | -110M | -249M | -241M | -222M | -413M | -158M | -158M |
| Owner Earnings | 307M | -86M | -229M | -207M | -211M | -404M | -155M | -155M |
| CapEx | 21M | 27M | 26M | 42M | 21M | 20M | 14M | 14M |
| Maint. CapEx | 845K | 3.2M | 6.2M | 8.1M | 10M | 11M | 11M | 11M |
| Growth CapEx | 20M | 24M | 20M | 34M | 11M | 9.4M | 3.4M | 3.4M |
| D&A | 845K | 3.2M | 6.2M | 8.1M | 10M | 11M | 11M | 11M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -287M |
| Cash & Equiv. | 210M | 83M | 456M | 689M | 786M | 1.3B | 287M | 287M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | N/A | N/A | N/A | N/A | N/A | 0.48 | 0.61 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | N/A | N/A | N/A | N/A | N/A | 1.3B | 1.0B | 1.0B |
| Total Assets | 3.7M | 28M | 40M | 38M | 56M | 1.8B | 1.7B | 1.7B |
| Total Liabilities | N/A | N/A | N/A | N/A | N/A | 597M | 630M | 630M |
| Intangibles | N/A | N/A | N/A | N/A | 3.4M | 4.1M | 2.2M | 2.2M |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Working Capital | N/A | N/A | N/A | N/A | N/A | 1.3B | 1.0B | 1.0B |
| Current Assets | N/A | N/A | N/A | N/A | N/A | 1.5B | 1.3B | 1.3B |
| Current Liabilities | N/A | N/A | N/A | N/A | N/A | 216M | 278M | 278M |
| Per Share Data | ||||||||
| EPS | -0.01 | -0.51 | -1.13 | -1.43 | -1.40 | -1.47 | -0.48 | -0.48 |
| Owner EPS | 1.10 | -0.43 | -0.97 | -0.73 | -0.66 | -1.15 | -0.42 | -0.42 |
| Book Value | N/A | N/A | N/A | N/A | N/A | 3.55 | 2.82 | 2.82 |
| Cash Flow/Share | 1.11 | -0.42 | -0.95 | -0.70 | -0.63 | -1.12 | -0.39 | -0.45 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 278.4M | 199.2M | 235.7M | 282.2M | 318.8M | 352.6M | 368.8M | 368.8M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -46.3 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | N/A | 16.9 | 11.5 | 7.9 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | 76.2 | 29.6 | 13.1 |
| FCF Yield | N/A | N/A | -3.5% | -1.8% | -1.5% | -2.0% | -1.3% | -1.9% |
| Market Cap | N/A | N/A | 7.1B | 13.6B | 15.3B | 21.1B | 12.0B | 8.2B |
| Avg. Price | N/A | N/A | 32.26 | 38.29 | 44.33 | 61.66 | 50.36 | 22.22 |
| Year-End Price | N/A | N/A | 29.97 | 48.35 | 48.05 | 59.81 | 32.49 | 22.22 |
Legend Biotech Corp passes 0 of 9 quality checks, indicating weak fundamentals.
Legend Biotech Corp (LEGN) has a debt-to-equity ratio of 0.61. This indicates moderate leverage.
Legend Biotech Corp (LEGN) reported earnings per share (EPS) of $-0.48 in its most recent fiscal year.
Legend Biotech Corp (LEGN) has a return on equity (ROE) of -15.4%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 7 years of financial data for Legend Biotech Corp (LEGN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Legend Biotech Corp (LEGN) has a book value per share of $2.82, based on its most recent annual SEC filing.
No recent press releases.